Non-selective beta blocker use is associated with improved short-term survival in patients with cirrhosis referred for liver transplantation.

NSBB use in patients with cirrhosis undergoing liver transplant evaluation is associated with better short-term survival. Nevertheless, ongoing tolerance of NSBB in this population is dynamic and may select a subset of patients with better hemodynamic reserve.